| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 12,126,646 | 12,126,646 |
| Net increase (decrease) in cash | 6,983,162 | 8,731,868 |
| Cash and cash equivalents at beginning of period | 3,455 | - |
| Cash and cash equivalents at end of period | 6,986,617 | - |
Apimeds Pharmaceuticals US, Inc. (APUS)
Apimeds Pharmaceuticals US, Inc. (APUS)